With the introduction of new products into Europe, European sales now account for over 40% of Osseon Therapeutics, Inc. sales, according to a report by company officials. They claim that Osseon’s newest product, the Osseoflex SB, a steerable bone tamp, is the first technological advance in vertebral augmentation devices in years. Distribution is now in six EU countries.
Osseon Expands in Europe With Osseoflex SB
1 min read Premium comments
Secondary
The former president of Osseon, Douglas Clark, has rejoined the company, via a seat on the Board of Directors. Clark has over 25 years of experience in medical device sales, sales management and business development. Osseon’s new Director of Sales, Jon Nolan, has worked in sales and surgeon training at Zimmer Spine, Johnson & Johnson, Stryker Corporation, and VERTEBRON, Inc..
Osseon Therapeutics is headquartered in Santa Rosa, California, and is dedicated to developing and commercializing state of the art medical devices for minimally invasive treatments for degenerative bone and joint disease, including the treatment of vertebral compression fractures.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.